Home > Insider Trading > Minerva Neurosciences Inc.

Minerva Neurosciences Inc. (NERV)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
11 - 19

Minerva Neurosciences, Inc (NERV): Are Hedge Funds Right About This Stock?

It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not...

Keep Reading →

November 11th, 2019 - Hedge Funds News

Is Minerva Neurosciences, Inc (NERV) A Good Stock To Buy?

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.

Keep Reading →

June 28th, 2019 - Hedge Funds News

Hedge Funds Aren't Crazy About Minerva Neurosciences Inc (NERV) Anymore

Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required...

Keep Reading →

December 12th, 2016 - Hedge Funds News

Baker Bros. Opened Positions In These 5 Healthcare Stocks

Julian Baker and Felix Baker founded Baker Bros. Advisors in 2000.

Keep Reading →

October 16th, 2016 - Hedge Fund Analysis Hedge Funds News

Here’s Why We’re Excited About The Upcoming Minerva Neurosciences Inc (NERV) Data

Minerva Neurosciences Inc (NASDAQ:NERV) just served up an update as to the progress of its two lead programs, and the company has remained relatively flat on the insight.

Keep Reading →

September 28th, 2016 - News Stock Analysis

Kingsway Financial Services Inc. (USA) (KFS) and Two Pharmaceutical Companies Register Insider Buying

The U.S. Securities and Exchange Commission prohibits executives and Board members from trading their company’s stock if they possess material non-public information about their company.

Keep Reading →

June 22nd, 2016 - Insider Trading News

Minerva Neurosciences Inc (NERV) Shares Skyrocket Following Successful Schizophrenia Drug Trial

Shares of Minerva Neurosciences Inc (NASDAQ:NERV) have surged by more than 235% today after the company announced positive results from the Phase IIb trial of its antidepressant drug candidate MIN-101...

Keep Reading →

May 26th, 2016 - Hedge Funds Market Movers News

13D Filing: Care Capital and Minerva Neurosciences, Inc. (NERV)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d...

Keep Reading →

April 7th, 2016 - Hedge Funds